Article
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood - 2 Mar 2017
Knapper Steven, Russell Nigel, Gilkes Amanda, Hills Robert K, Gale Rosemary E, Cavenagh James D, Jones Gail, Kjeldsen Lars, Grunwald Michael R, Thomas Ian, Konig Heiko, Levis Mark J, Burnett Alan K
Abstract excerpt
The clinical benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small molecule therapy to standard first-line treatment of acute myeloid leukemia (AML) has not yet been established. As part of the UK AML15 and AML17 trials, patients with previously untreated AML and confirmed FLT3-activating mutations, mostly younger than 60 years, were randomly assigned either to receive oral lestaurtinib (CEP701) or...
Topics
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carbazoles
- Child
- Child, Preschool
- Consolidation Chemotherapy
- Disease-Free Survival
- Female